Major Depressive Disorder Patients Emphasize Long-Term Nature Of Disease In Feedback Meeting
Executive Summary
Externally hosted patient focused drug development meeting in MDD brings timely messages to US FDA during period of active regulatory review of new applications. Patients stress need for fewer side effects to encourage long-term medication use, and also want fast-acting meds that can “jump start” lifestyle changes.
You may also be interested in...
Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?
By reducing regulatory uncertainty, US FDA’s Breakthrough Therapy Designation is helping adventurous sponsors try new trial designs and new mechanism in the long-stagnant field of psychiatry drug development.
FDA Opioid Review Adds Another Push For Advisory Committee Overhaul
External report on the US FDA’s response to the opioid epidemic includes detailed recommendations for enhancements to the advisory committee review process. That dovetails with the agency’s ongoing look at how best to use the expert panels.
US FDA Food Safety Overhaul Will Have Ripple Effects For Drug Inspections
A restructuring of FDA’s food safety operations includes changes to the agency-wide office that handles all inspections, including those of drug manufacturers. It’s another shift in the delicate balancing of centralized management of ORA with the specific needs and priorities of the different centers.